Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

A new scoring system for malignant astrocytomas.

Z Kojadinovic¹, V Papic, T Cigic

¹Clinic of Neurosurgery, University Clinical Center Novi Sad, Novi Sad, Serbia and Montenegro. koja@eunet.yu

Zentralblatt Fur Neurochirurgie

|April 30, 2008

Summary

A new Malignant Astrocytoma Score (MAS) was developed for supratentorial astrocytoma prognosis. This validated scoring system is more accurate than existing methods and applicable globally.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autism treatment with stem cells: a case report.

European review for medical and pharmacological sciences·2020

Same author

The quality of life of patients after a lumbar microdiscectomy: a four-year monitoring study.

Clinical neurology and neurosurgery·2010

Same author

[Functional magnetic resonance imaging in brain tumour neurosurgical resection risk assessment].

Acta chirurgica Iugoslavica·2010

Same author

The basic morphological characteristics of astrocytomas in Vojvodina in the period 2001-2006.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2010

Same author

[War injuries of blood vessels of the extremities].

Acta chirurgica Iugoslavica·2002

Same author

[Recovery of facial nerve function using sural nerve transplantation after its injury in acoustic nerve surgery].

Medicinski pregled·1999

Area of Science:

Neuro-oncology
Clinical Prognostics
Medical Scoring Systems

Background:

Existing scoring systems for malignant astrocytoma lack widespread acceptance.
There is a need for a universally applicable scoring system for supratentorial malignant astrocytoma.

Purpose of the Study:

To develop a novel scoring system for supratentorial malignant astrocytoma.
To create a tool usable in both developed and developing healthcare settings.

Main Methods:

A cohort of 128 patients with supratentorial malignant astrocytoma (WHO grade III or IV) was analyzed.
Prognostic value of 35 parameters was tested to identify key factors for survival.
The Malignant Astrocytoma Score (MAS) was created using age, Karnofsky performance status (KPS), initial seizure, and histopathological grade.

More Related Videos

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Main Results:

The MAS demonstrated strong predictive accuracy for 6-, 12-, and 18-month survival (AUCs 0.729, 0.755, 0.927).
MAS outperformed established systems like MRC (AUCs 0.673, 0.637, 0.888) and RTOG (AUCs 0.672, 0.700, 0.854).
Key prognostic factors identified included age, KPS, initial seizure, and histopathological grade.

Conclusions:

The Malignant Astrocytoma Score (MAS) is a valuable tool for assessing disease severity and predicting outcomes in malignant supratentorial astrocytoma.
MAS offers superior accuracy and incorporates widely accepted prognostic factors.
Its bedside applicability makes it suitable for diverse clinical environments, including resource-limited settings.